Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18879995 | NOVEL 5-DEHYDRO-2-DEOXYGLUCONOKINASE VARIANT AND METHOD FOR PRODUCING 5’-INOSINIC ACID USING SAME | December 2024 | May 2025 | Allow | 5 | 0 | 0 | No | No |
| 18970552 | S. PYOGENES CAS9 MUTANT GENES AND POLYPEPTIDES ENCODED BY SAME | December 2024 | May 2025 | Allow | 5 | 1 | 0 | No | No |
| 18919946 | FUSION POLYPEPTIDES FOR PRODUCTION OF 7-DEHYDROCHOLESTEROL AND METHODS OF USE THEREOF | October 2024 | February 2025 | Allow | 4 | 0 | 1 | No | No |
| 18914016 | COMPOSITIONS FOR PREVENTING OR TREATING CORONAVIRUS INFECTIONS | October 2024 | September 2025 | Allow | 11 | 1 | 1 | No | No |
| 18886925 | HOST CELLS COMPRISING A RECOMBINANT CASEIN PROTEIN AND A RECOMBINANT KINASE PROTEIN | September 2024 | January 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 18882318 | RECOMBINANT CELL WALL HYDROLASES | September 2024 | December 2024 | Allow | 3 | 0 | 1 | No | No |
| 18734239 | METHOD FOR EXPANDING PROPAGATION OF METARHIZIUM RILEYI MR006 AND USE THEREOF | June 2024 | April 2025 | Allow | 10 | 2 | 0 | No | No |
| 18641530 | ENZYMATIC PRODUCTION OF HEXOSES | April 2024 | November 2025 | Allow | 19 | 1 | 0 | No | No |
| 18614665 | BONE GELATIN PROCESS | March 2024 | August 2024 | Allow | 4 | 1 | 0 | No | No |
| 18613508 | OMNI-103 CRISPR NUCLEASE | March 2024 | August 2025 | Allow | 17 | 1 | 0 | No | No |
| 18600332 | ENZYMATIC METHOD FOR PREPARING REBAUDIOSIDE J | March 2024 | April 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18688056 | POLYPEPTIDES AND USES THEREOF | February 2024 | May 2025 | Allow | 14 | 1 | 1 | No | No |
| 18586929 | ENZYMES WITH RUVC DOMAINS | February 2024 | December 2024 | Allow | 9 | 2 | 1 | No | No |
| 18582803 | Chimeric endolysin polypeptide | February 2024 | July 2024 | Allow | 5 | 0 | 0 | Yes | No |
| 18291954 | LARGE SCALE PURIFICATION OF ANTIBODIES | January 2024 | July 2025 | Allow | 17 | 2 | 1 | No | No |
| 18545977 | SUPPRESSION OF PAIN BY GENE EDITING | December 2023 | August 2025 | Allow | 20 | 1 | 1 | No | No |
| 18544368 | TYPE III COLLAGEN PEPTIDE AND PREPARATION METHOD THEREOF | December 2023 | June 2024 | Allow | 6 | 1 | 0 | No | No |
| 18537715 | BLOOD GLUCOSE STABILIZING METHODS AND COMPOSITIONS | December 2023 | December 2025 | Allow | 24 | 2 | 1 | No | No |
| 18532665 | SIALYLATED GLYCOPROTEIN COMPOSITIONS AND USES THEREOF | December 2023 | April 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18516160 | SOLUBILIZATION OF MSW WITH BLEND ENZYMES | November 2023 | March 2025 | Abandon | 16 | 0 | 1 | No | No |
| 18513879 | Compositions and Methods for Treating Celiac Sprue Disease | November 2023 | November 2025 | Allow | 23 | 2 | 1 | No | No |
| 18561246 | MICROBIAL STRAIN EXPRESSING AN INVERTASE/SUCROSE HYDROLASE | November 2023 | September 2025 | Allow | 22 | 2 | 1 | No | No |
| 18505972 | ENGINEERED PYROCOCCUS ENZYMES AND USES THEREOF | November 2023 | February 2025 | Allow | 15 | 1 | 0 | Yes | No |
| 18558880 | Optimization of a Halophilic PHB Depolymerase for Industrial Applications | November 2023 | November 2025 | Allow | 24 | 3 | 1 | No | No |
| 18489954 | Agarase Mutant with Improved Thermal Stability and Application Thereof | October 2023 | April 2024 | Allow | 6 | 1 | 0 | No | No |
| 18287223 | PROTEIN COMPLEX INCLUDING BOTULINUM TOXIN TRANSLOCATION DOMAIN AND ENDOLYSIN AND ANTIBACTERIAL COMPOSITION INCLUDING SAME | October 2023 | August 2024 | Allow | 10 | 2 | 0 | Yes | No |
| 18484305 | BLOOD GLUCOSE STABILIZING METHODS AND COMPOSITIONS | October 2023 | March 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18474786 | GENETICALLY MODIFIED ORGANISMS FOR PRODUCING PSYCHOTROPIC ALKALOIDS | September 2023 | June 2024 | Allow | 9 | 1 | 1 | No | No |
| 18473990 | COMPOSITIONS AND METHODS FOR EPIGENETIC REGULATION OF HBV GENE EXPRESSION | September 2023 | February 2025 | Abandon | 17 | 2 | 1 | No | No |
| 18467362 | URIDINE DIPHOSPHATE-DEPENDENT GLYCOSYLTRANSFERASE ENZYME | September 2023 | July 2025 | Allow | 22 | 2 | 1 | No | No |
| 18463864 | HOST CELLS COMPRISING A RECOMBINANT CASEIN PROTEIN AND A RECOMBINANT KINASE PROTEIN | September 2023 | August 2024 | Allow | 11 | 2 | 1 | No | No |
| 18456333 | RECOMBINANT YEAST AND USE THEREOF | August 2023 | January 2025 | Allow | 17 | 1 | 1 | Yes | No |
| 18264101 | SUBTILISIN VARIANTS AND THEIR USE | August 2023 | October 2025 | Allow | 27 | 2 | 1 | Yes | No |
| 18364419 | ENGINEERED GLYCOSYLTRANSFERASES AND STEVIOL GLYCOSIDE GLUCOSYLATION METHODS | August 2023 | June 2025 | Allow | 22 | 1 | 1 | Yes | No |
| 18353339 | MODIFIED DDAH POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCING MOIETY, IMPROVED PHARMACOLOGY AND THEIR USES | July 2023 | March 2026 | Abandon | 32 | 2 | 1 | No | No |
| 18220808 | Applications of Engineered Streptococcus Canis Cas9 Variants on Single-Base PAM Targets | July 2023 | April 2025 | Allow | 21 | 1 | 1 | No | No |
| 18347473 | 2,3-Butanediol Production, Methyl Ethyl Ketone Production, and Induction of Drought Tolerance in Plants | July 2023 | February 2026 | Allow | 32 | 0 | 1 | Yes | No |
| 18342853 | P21 MRNA TARGETING DNAZYMES | June 2023 | November 2023 | Allow | 5 | 0 | 1 | Yes | No |
| 18340344 | RECEPTOR/HISTIDINE KINASE FUSION CONSTRUCTS AND USES THEREOF | June 2023 | January 2025 | Abandon | 19 | 0 | 1 | No | No |
| 18338255 | METHODS FOR PRODUCTION OF HUMAN RECOMBINANT ARGINASE 1 AND USES THEREOF | June 2023 | February 2025 | Allow | 20 | 1 | 0 | No | No |
| 18325199 | E. coli Deficient in Lon and SulA for Gene Targeting | May 2023 | January 2025 | Allow | 19 | 0 | 1 | No | No |
| 18039210 | GLUTAMATE-CYSTEINE LIGASE VARIANT AND METHOD FOR PRODUCING GLUTATHIONE USING SAME | May 2023 | January 2026 | Allow | 32 | 0 | 0 | Yes | No |
| 18322480 | GENETICALLY ENCODED BIOSENSORS | May 2023 | September 2024 | Allow | 16 | 1 | 0 | No | No |
| 18317915 | GAS VESICLE EXPRESSION SYSTEMS, GAS VESICLE CONSTRUCTS AND RELATED GENETIC CIRCUITS, VECTORS, MAMMALIAN CELLS, HOSTS, COMPOSITIONS, METHODS AND SYSTEMS | May 2023 | October 2024 | Allow | 17 | 1 | 0 | No | No |
| 18314859 | Chimeric endolysin polypeptide | May 2023 | September 2023 | Allow | 4 | 0 | 0 | No | No |
| 18313048 | COMPOSITIONS AND METHODS FOR DETECTION AND MEASUREMENT OF RNA MODIFICATIONS THROUGH TARGETED RNA EDITING | May 2023 | August 2024 | Allow | 15 | 1 | 0 | No | No |
| 18310225 | STEVIOL GLYCOSIDE HEXOSE TRANSFERASE AND GENE CODING FOR SAME | May 2023 | June 2025 | Abandon | 25 | 1 | 1 | No | No |
| 18248291 | TRANSCRIPTION ACTIVE COMPLEX TARGETING CANCER DRUG FROM VIRAL PROTEIN SEQUENCE | April 2023 | November 2025 | Allow | 31 | 0 | 0 | Yes | No |
| 18296250 | METHODS OF INACTIVATING VIRAL CONTAMINANTS | April 2023 | January 2026 | Abandon | 34 | 2 | 1 | No | No |
| 18130202 | RNA-GUIDED ENDONUCLEASE FUSION POLYPEPTIDES AND METHODS OF USE THEREOF | April 2023 | August 2025 | Allow | 28 | 2 | 1 | No | No |
| 18130199 | RNA-GUIDED ENDONUCLEASE FUSION POLYPEPTIDES AND METHODS OF USE THEREOF | April 2023 | May 2025 | Allow | 26 | 2 | 1 | No | No |
| 18194131 | COMPOSITIONS AND METHODS FOR ENZYME IMMOBILIZATION | March 2023 | December 2025 | Allow | 33 | 3 | 1 | No | No |
| 18184476 | BLOOD GLUCOSE STABILIZING METHODS AND COMPOSITIONS | March 2023 | September 2023 | Allow | 6 | 1 | 0 | Yes | No |
| 18182817 | COMPOSITIONS AND METHODS COMPRISING LYSIN PLYCP025 AND DERIVATIVES THEREOF | March 2023 | June 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18120639 | POLYMERASES, COMPOSITIONS, AND METHODS OF USE | March 2023 | May 2024 | Allow | 15 | 1 | 0 | No | No |
| 18182948 | INCORPORATION OF INTERNAL POLYA-ENCODED POLY-LYSINE SEQUENCE TAGS AND THEIR VARIATIONS FOR THE TUNABLE CONTROL OF PROTEIN SYNTHESIS IN BACTERIAL AND EUKARYOTIC CELLS | March 2023 | May 2025 | Allow | 26 | 2 | 1 | No | No |
| 18178917 | THERAPEUTIC VARIANT ALPHA-2-MACROGLOBULIN COMPOSITIONS | March 2023 | August 2024 | Allow | 17 | 1 | 1 | No | No |
| 18024404 | METHODS FOR TREATING BONE MINERALIZATION DISORDERS | March 2023 | February 2026 | Allow | 35 | 1 | 1 | No | No |
| 18174552 | SYNTHETIC MINIATURE CRISPR-CAS (CASMINI) SYSTEM FOR EUKARYOTIC GENOME ENGINEERING | February 2023 | May 2025 | Allow | 27 | 3 | 1 | Yes | No |
| 18165470 | BETA-LACTAMASES WITH IMPROVED PROPERTIES FOR THERAPY | February 2023 | September 2023 | Allow | 7 | 1 | 0 | Yes | No |
| 18162243 | CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF | January 2023 | January 2025 | Allow | 24 | 1 | 1 | No | No |
| 18006372 | OMNI-103 CRISPR NUCLEASE | January 2023 | January 2024 | Allow | 12 | 1 | 1 | No | No |
| 18156025 | PROCESS FOR MANIPULATING THE LEVEL OF GLYCAN CONTENT OF A GLYCOPROTEIN | January 2023 | October 2025 | Abandon | 33 | 2 | 0 | Yes | No |
| 18098647 | MODIFIED CLEAVASES, USES THEREOF AND RELATED KITS | January 2023 | February 2026 | Abandon | 37 | 1 | 0 | No | No |
| 18148818 | COMPOSITIONS COMPRISING A VARIANT CAS12I4 POLYPEPTIDE AND USES THEREOF | December 2022 | May 2023 | Allow | 5 | 0 | 0 | No | No |
| 18088367 | COMPOSITIONS AND METHODS USING METHANOTROPHIC S-LAYER PROTEINS FOR EXPRESSION OF HETEROLOGOUS PROTEINS | December 2022 | February 2025 | Abandon | 26 | 0 | 1 | No | No |
| 18145042 | UnGE promoter sequence and its uses | December 2022 | April 2024 | Allow | 16 | 1 | 2 | No | No |
| 18068256 | COMPOSITIONS FOR TREATING ECTOPIC CALCIFICATION DISORDERS, AND METHODS USING SAME | December 2022 | October 2024 | Allow | 22 | 1 | 1 | No | No |
| 18066482 | REPRESSIBLE CONTROL OF GENE EXPRESSION | December 2022 | June 2024 | Allow | 18 | 1 | 1 | No | No |
| 18064199 | HOST CELLS COMPRISING A RECOMBINANT CASEIN PROTEIN AND A RECOMBINANT KINASE PROTEIN | December 2022 | August 2023 | Allow | 9 | 1 | 1 | Yes | No |
| 18060797 | E. COLI-BASED PRODUCTION OF BETA-LACTAMASE | December 2022 | January 2024 | Allow | 13 | 1 | 0 | No | No |
| 18056385 | POLYPEPTIDE HAVING CEPHALOSPORIN C ACYLASE ACTIVITY AND USE THEREOF | November 2022 | April 2024 | Allow | 17 | 2 | 1 | Yes | No |
| 18056126 | GLYCOSYLATION OF PROTEINS | November 2022 | June 2024 | Abandon | 19 | 1 | 1 | No | No |
| 17995816 | ENZYMATIC METHOD FOR PREPARATION OF CMP-NEU5AC | October 2022 | December 2024 | Allow | 26 | 0 | 1 | No | No |
| 17915875 | HELPER FACTORS FOR EXPRESSING PROTEINS IN YEAST | September 2022 | October 2025 | Allow | 36 | 1 | 0 | No | No |
| 17949489 | ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES | September 2022 | May 2023 | Allow | 8 | 1 | 0 | No | No |
| 17933406 | XYLITOL PRODUCING METSCHNIKOWIA SPECIES | September 2022 | April 2024 | Abandon | 19 | 0 | 1 | No | No |
| 17930683 | INSECTICIDAL PEPTIDE PRODUCTION AND COMBINATION OF CYSTEINE RICH PEPTIDES | September 2022 | May 2025 | Allow | 33 | 2 | 1 | Yes | No |
| 17929986 | HETEROLOGOUS PROTEASE EXPRESSION FOR IMPROVING ALCOHOLIC FERMENTATION | September 2022 | September 2025 | Abandon | 36 | 3 | 1 | No | No |
| 17904571 | HYPOALLERGENIC RECOMBINANT MILK PROTEINS AND COMPOSITIONS COMPRISING THE SAME | August 2022 | May 2024 | Allow | 21 | 1 | 1 | Yes | No |
| 17800397 | PROTEIN CRYSTAL PRODUCTION METHOD AND CRYSTALLINE STRUCTURE ANALYSIS METHOD | August 2022 | January 2026 | Allow | 41 | 1 | 1 | No | No |
| 17820316 | Novel polypeptides and antibiotics against Gram-negative bacterium comprising the same | August 2022 | May 2024 | Allow | 21 | 2 | 1 | Yes | No |
| 17818389 | CONSTRUCTION OF RECOMBINANT SACCHAROMYCES CEREVISIAE FOR SYNTHESIZING CARMINIC ACID AND APPLICATION THEREOF | August 2022 | July 2023 | Allow | 11 | 1 | 1 | No | No |
| 17794408 | MUTANTS OF A FILAMENTOUS FUNGAL CELL HAVING INCREASED PRODUCTIVITY IN THE PRODUCTION OF A POLYPEPTIDE | July 2022 | January 2026 | Allow | 42 | 1 | 0 | No | No |
| 17813977 | Solid Medium for Coriolus Versicolor, and Preparation Method and Use | July 2022 | May 2024 | Allow | 22 | 1 | 1 | No | No |
| 17794500 | ANTI-PD-L1 ANTIBODIES | July 2022 | November 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17870190 | S. PYOGENES CAS9 MUTANT GENES AND POLYPEPTIDES ENCODED BY SAME | July 2022 | August 2024 | Allow | 24 | 1 | 1 | No | No |
| 17812826 | GENETIC ENGINEERING OF FUNGI TO MODULATE TRYPTAMINE EXPRESSION | July 2022 | October 2023 | Allow | 15 | 2 | 1 | No | No |
| 17812157 | RECOMBINANT YEAST AND USE THEREOF | July 2022 | September 2023 | Abandon | 14 | 1 | 0 | No | No |
| 17862354 | INHIBITION OF UNINTENDED MUTATIONS IN GENE EDITING | July 2022 | August 2023 | Allow | 13 | 0 | 1 | No | No |
| 17855507 | Applications of Engineered Streptococcus Canis Cas9 Variants on Single-Base PAM Targets | June 2022 | February 2023 | Allow | 8 | 0 | 0 | Yes | No |
| 17850516 | MODIFIED CLEAVASES, USES THEREOF AND RELATED KITS | June 2022 | August 2023 | Allow | 14 | 1 | 0 | No | No |
| 17844371 | SYNTHETIC OPLOPHORUS LUCIFERASES WITH ENHANCED LIGHT OUTPUT | June 2022 | February 2023 | Allow | 8 | 0 | 0 | No | No |
| 17786786 | SERUM ALBUMIN-BINDING FIBRONECTIN TYPE III DOMAINS AND USES THEREOF | June 2022 | May 2025 | Allow | 35 | 0 | 0 | Yes | No |
| 17841639 | Applications of Recombined ScCas9 Enzymes for PAM-free DNA Modification | June 2022 | September 2025 | Allow | 39 | 1 | 0 | Yes | No |
| 17783639 | AN ACTIVATED CYSTEINE-DIRECTED POLYPEPTIDE LIGATION TECHNIQUE | June 2022 | November 2025 | Allow | 41 | 1 | 0 | No | No |
| 17783076 | METHOD FOR PRODUCING PEPTIDE CONTAINING NON-NATURAL AMINO ACID | June 2022 | January 2026 | Allow | 44 | 1 | 1 | No | No |
| 17805626 | ENZYMATIC METHOD FOR PREPARING REBAUDIOSIDE J | June 2022 | January 2024 | Allow | 19 | 1 | 1 | No | No |
| 17825484 | ENZYMATIC PRODUCTION OF HEXOSES | May 2022 | April 2024 | Allow | 22 | 2 | 0 | Yes | No |
| 17750758 | RECOMBINASE POLYMERASE AMPLIFICATION | May 2022 | October 2024 | Allow | 28 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner NOAKES, SUZANNE MARIE.
With a 20.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 18.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner NOAKES, SUZANNE MARIE works in Art Unit 1656 and has examined 1,337 patent applications in our dataset. With an allowance rate of 70.9%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 27 months.
Examiner NOAKES, SUZANNE MARIE's allowance rate of 70.9% places them in the 34% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by NOAKES, SUZANNE MARIE receive 1.36 office actions before reaching final disposition. This places the examiner in the 20% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by NOAKES, SUZANNE MARIE is 27 months. This places the examiner in the 71% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +24.2% benefit to allowance rate for applications examined by NOAKES, SUZANNE MARIE. This interview benefit is in the 70% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 31.9% of applications are subsequently allowed. This success rate is in the 66% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 54.9% of cases where such amendments are filed. This entry rate is in the 81% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 120.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 82% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 87.2% of appeals filed. This is in the 80% percentile among all examiners. Of these withdrawals, 85.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 65.5% are granted (fully or in part). This grant rate is in the 70% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 9.4% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.6% of allowed cases (in the 76% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.